Key Points
- Insider sale: Daljit Singh Aurora sold 114,703 shares on Nov. 11 at an average price of $2.68, totaling about $307,404, according to the SEC filing.
- Shares traded up to $2.71 on Friday with 101,897 shares changing hands (vs. average volume ~1.89M); the company has a market capitalization of ~$452.8M and a 1‑year range of $0.61–$11.77.
- Neumora is a clinical‑stage biopharma developing navacaprant (Phase 3 for major depressive disorder); it recently missed quarterly EPS by $0.01 and carries a consensus analyst rating of "Hold" with a $7.43 average price target.
Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) insider Daljit Singh Aurora sold 114,703 shares of the company's stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $2.68, for a total transaction of $307,404.04. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Neumora Therapeutics Trading Up 0.7%
Shares of NASDAQ NMRA traded up $0.02 during trading on Friday, hitting $2.71. 101,897 shares of the company traded hands, compared to its average volume of 1,885,519. The firm has a market capitalization of $452.81 million, a P/E ratio of -1.83 and a beta of 2.98. The company has a quick ratio of 6.85, a current ratio of 6.85 and a debt-to-equity ratio of 0.15. The company has a 50-day moving average price of $2.06 and a 200-day moving average price of $1.48. Neumora Therapeutics, Inc. has a 1 year low of $0.61 and a 1 year high of $11.77.
Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.01). On average, equities analysts predict that Neumora Therapeutics, Inc. will post -1.61 EPS for the current year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Personalized Indexing Management LLC increased its stake in Neumora Therapeutics by 10.7% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 64,429 shares of the company's stock worth $117,000 after buying an additional 6,233 shares during the period. Invesco Ltd. increased its position in shares of Neumora Therapeutics by 6.8% during the second quarter. Invesco Ltd. now owns 132,038 shares of the company's stock worth $97,000 after acquiring an additional 8,383 shares during the last quarter. CWM LLC lifted its stake in shares of Neumora Therapeutics by 41.8% in the second quarter. CWM LLC now owns 35,750 shares of the company's stock worth $26,000 after acquiring an additional 10,537 shares in the last quarter. Legacy Private Trust Co. acquired a new position in shares of Neumora Therapeutics in the third quarter worth about $25,000. Finally, Cerity Partners LLC boosted its holdings in Neumora Therapeutics by 7.2% in the second quarter. Cerity Partners LLC now owns 324,219 shares of the company's stock valued at $238,000 after purchasing an additional 21,714 shares during the last quarter. 47.65% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
NMRA has been the topic of several research analyst reports. Needham & Company LLC lifted their price objective on Neumora Therapeutics from $6.00 to $8.00 and gave the company a "buy" rating in a research note on Tuesday, October 28th. JPMorgan Chase & Co. cut shares of Neumora Therapeutics from a "neutral" rating to an "underweight" rating in a research report on Tuesday, September 16th. Guggenheim upgraded shares of Neumora Therapeutics from a "neutral" rating to a "buy" rating and set a $14.00 price objective for the company in a research note on Monday, October 27th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Neumora Therapeutics in a research report on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, Neumora Therapeutics currently has an average rating of "Hold" and a consensus price target of $7.43.
Get Our Latest Stock Report on NMRA
About Neumora Therapeutics
(
Get Free Report)
Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
